A Clinical Trial to Evaluate the Benefit of Adding Octreotide (SMS 201-995 PA LAR) to Tamoxifen Alone or to Tamoxifen and Chemotherapy [doxorubicin + cyclophosphamide] in Patients With Axillary Node-Negative, Estrogen-Receptor-Positive, Primary Invasive Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 16 Jun 2016
At a glance
- Drugs Octreotide (Primary) ; Tamoxifen (Primary) ; Cyclophosphamide; Doxorubicin
- Indications Early breast cancer
- Focus Therapeutic Use
- 10 Oct 2005 New trial record.